Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The serine/threonine kinase B-Raf and epidermal growth factor receptor (EGFR) are crucial in cell signaling pathways regulating proliferation and survival.
• Activating mutations in BRAF and EGFR are implicated in various human cancers, including non-small cell lung carcinomas treated with EGFR inhibitors.
• Adrenocortical carcinoma (ACC) is a rare malignancy where targeted therapy options are limited.

Purpose of the Study:

• To investigate the prevalence of mutations in key signaling pathway genes (BRAF, KRAS, NRAS, EGFR) within adrenal carcinomas.
• To assess the potential for targeted therapies by analyzing the functional impact of identified mutations on downstream signaling.
• To identify potential therapeutic targets for adrenocortical carcinoma based on genetic alterations.

Main Methods:

• DNA sequencing was employed to analyze exons 11 and 15 of BRAF, exons 1 and 2 of KRAS and NRAS, and exons 18-21 of EGFR.
• The study included 35 adrenal carcinoma tumor specimens and two cell lines.
• Immunohistochemistry was used to evaluate the phosphorylation status of MEK, ERK, and EGFR (Tyr 992) in tumor tissues.

Main Results:

• Mutations were detected in 5.7% of adrenal carcinomas for BRAF and 11.4% for EGFR.
• KRAS and NRAS mutations were found in one specimen each.
• BRAF- and EGFR-mutant tumors showed increased phosphorylation of MEK and ERK, while EGFR-mutant tumors displayed heightened EGFR phosphorylation.

Conclusions:

• BRAF, RAS, and EGFR mutations are present in a subset of human adrenocortical carcinomas.
• The observed mutations correlate with increased pathway activation, suggesting these signaling cascades are oncogenic drivers in ACC.
• Targeted inhibitors of the Ras/Raf/MEK/ERK and EGFR pathways represent promising therapeutic strategies for selected ACC patients with specific mutations.